Moderna has withdrawn its application to approve the influenza-Covid-19 combination vaccine, intending to resubmit the application with additional data later

The decision follows consultations with the FDA, which has requested new clinical trials for Covid-19 booster doses. Moderna shares fell 1.4% amid declining revenue from Covid-19 vaccines and concerns about the nomination of Robert F. Kennedy Jr. to be secretary of the Health Department. The FDA is expected to decide on the next-generation Covid-19 vaccine, part of the combination vaccine, with no anticipated delays.